Impact of genomic aberrations including chromosome 1 abnormalities on the outcome of patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone.
Chang
Hong
H
Department of Laboratory Hematology, University Health Network, Toronto, Canada. Hong.Chang@uhn.on.ca
Jiang
Allan
A
Qi
Connie
C
Trieu
Young
Y
Chen
Christine
C
Reece
Donna
D